Compare DXPE & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXPE | CLDX |
|---|---|---|
| Founded | 1908 | N/A |
| Country | United States | United States |
| Employees | N/A | 198 |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 1998 | 1995 |
| Metric | DXPE | CLDX |
|---|---|---|
| Price | $144.70 | $30.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $154.00 | $46.60 |
| AVG Volume (30 Days) | 183.0K | ★ 631.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.25 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,247,043,000.00 | $12,743,000.00 |
| Revenue This Year | $9.31 | $111.39 |
| Revenue Next Year | $7.85 | $235.85 |
| P/E Ratio | $115.25 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $75.58 | $18.56 |
| 52 Week High | $183.91 | $35.83 |
| Indicator | DXPE | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 41.99 |
| Support Level | $141.08 | $28.30 |
| Resistance Level | $154.19 | $30.90 |
| Average True Range (ATR) | 9.10 | 1.52 |
| MACD | -2.94 | -0.41 |
| Stochastic Oscillator | 17.19 | 27.07 |
DXP Enterprises Inc is engaged in the business of distributing maintenance, repair and operating (MRO) products, equipment and service to customers in various end markets, including general industrial, energy, food & beverage, chemical, transportation, water and wastewater. The company operates through three business segments: Service Centers, Innovative Pumping Solutions and Supply Chain Services. The majority of revenue is derived from the Service Centers segment, which provides a wide range of MRO products in the rotating equipment, bearing, power transmission, hose, fluid power, metal working, fastener, industrial supply, safety products and safety services categories. Geographically, it generates the maximum revenue from the United States.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.